Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Open Access
- 31 October 2018
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 10 (1) , 1-10
Abstract
For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies. Pathways targeted for therapeutic intervention in autoimmune diseases can be modulated in the opposite sense in malignancy and infectious disease. We discuss the basic principles of the immune response, how these are co-opted in chronic infection and malignancy, and how these can be harnessed to treat disease. T cells are at the center of immunotherapy. We consider the complexity of T cell functional subsets, differentiation states, and extrinsic and intrinsic influences in the design, success, and lessons from immunotherapies. The integral role of checkpoints in the immune response is highlighted by the rapid advances in FDA approvals and the use of therapeutics that target the CTLA-4 and PD-1/PD-L1 pathways. We discuss the distinct and overlapping mechanisms of CTLA-4 and PD-1 and how these can be translated to combination immunotherapy treatments. Finally, we discuss how the successes and challenges in cancer immunotherapies, such as the collateral damage of immune-related adverse events following checkpoint inhibition, are informing treatment of autoimmunity, infection, and malignancy.Keywords
This publication has 101 references indexed in Scilit:
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Emerging principles in protease-based drug discoveryNature Reviews Drug Discovery, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4 + T CellsScience, 2010
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009
- The Initial Phase of an Immune Response Functions to Activate Regulatory T CellsThe Journal of Immunology, 2009
- Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathwayJournal of Experimental Medicine, 2006